Source: Markets Insider

Cellphire: Cellphire Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Thrombosomes in Bleeding Thrombocytopenic Patients

ROCKVILLE, Md., May 27, 2021 /PRNewswire/ -- Cellphire Therapeutics, Inc., a biotechnology company developing next-generation platelet-based hemos...

Read full article »

Cellphire's Competitors | Cellphire's News | Cellphire's Financials

Followers on Owler

Est. Annual Revenue

$5.0-25M

Est. Employees

25-100

President & CEO

Michael Gaffney

CEO Approval Rating

90/100

Cellphire is a Maryland-based biotechnology company that develops and commercializes stabilized cellular materials to treat bleeding and blood-related ailments.